Sanofi, Pfizer Back $787M AI Biotech Raise

Earendil Labs raises $787M from Sanofi and Pfizer to scale its AI-native biologics platform and 40-plus drug pipeline

1 Apr 2026

AI drug discovery has attracted bold claims for years. Earendil Labs is now attracting bold money.

The Delaware-based biotechnology company announced $787 million in financing on March 20, 2026, one of the largest capital raises in the sector's history. Sanofi and the Biotech Development Fund, a vehicle created by Pfizer and Hillhouse, joined Dimension Capital, DST Global, and Luminous Ventures in backing the company. Together, they are betting that Earendil's model, which applies AI across the complete biologics R&D cycle, from disease target identification through molecular design and clinical candidate optimization, is not just promising but production-ready.

That pipeline reflects the ambition. More than 40 drug programs are in development, including HXN-1001, an antibody targeting inflammatory bowel disease now cleared for Phase 2 clinical trials. Multiple additional filings with US regulators are planned for 2026 and 2027.

What gives this raise particular weight is Sanofi's track record with the company. The French pharmaceutical giant has now backed Earendil across three consecutive deals, the largest a $2.56 billion collaboration signed in January 2026 to jointly develop drugs for autoimmune and inflammatory conditions. Repeat investment at that scale is harder to dismiss than a first-time bet. It suggests the platform is delivering results that matter to one of the industry's most demanding partners.

The timing is no coincidence. Patent expirations are projected to strip an estimated $230 billion from the American drug market between 2025 and 2030, leaving major players scrambling to rebuild pipelines faster and more cheaply than traditional methods allow. AI-native companies like Earendil, which treat machine learning as the core production engine rather than a bolt-on tool, have moved from the industry's periphery to its center of gravity.

Founder and CEO Jian Peng has said the capital will allow Earendil to operate at fundamentally different scale, advancing multiple programs toward the clinic while building an R&D organization with long-term reach. The pharmaceutical world will be watching every clinical milestone that follows.